Overview


According to FutureWise analysis the market for acute myeloid leukemia is expected to reach US$ 3.63 billion by 2031 at a CAGR of 10.37%.

The complex hematologic malignancy known as acute myeloid Leukemia (AML) is characterised by the clonal expansion of myeloid blasts in the bone marrow, and/or other organs. This type of acute Leukemia, which is more common in adults, is responsible for the majority of leukemia-related deaths in the United States each year. Large chromosomal translocations and mutations in the genes involved in hematopoietic proliferation are the causes of the rise in poorly formed myeloid cells. AML is a very heterogeneous disease; although cases can be divided into groups with favorable, intermediate, and unfavorable risks based on their cytogenetic profiles, prognosis within these groups varies greatly.

The typical age of diagnosis is 67 years, with 54% of patients receiving their diagnosis at 65 or older (and around a third of those receiving their diagnosis at or below 75 years old). As a result, the incidence of AML appears to be increasing as the population ages. Prolonged exposure to petrochemicals, solvents like benzene, insecticides, and ionizing radiation are environmental factors that have long been known to raise the risk of AML. Individual prognosis and management have been improved due to the discovery of recurrent genetic variants such as FLT3-ITD, NMP1, and CEBPA. Despite advancements in supportive care, a combination of chemotherapy regimens based on cytarabine and anthracyclines combined with allogeneic stem cell transplantation for suitable individuals remains to be the cornerstone of therapy. Elderly patients frequently can't endure such regimens and frequently carry a poor prognosis.

FutureWise Market Research has published a report that provides an insightful analysis of acute myeloid Leukemia market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the acute myeloid Leukemia market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Johnson & Johnson Private Limited
  • Pfizer Inc.
  • Abbott
  • AstraZeneca
  • Bayer
  • Celgene Corporation
  • Ambit Biosciences Corporation
  • Cyclacel Pharmaceuticals Inc.
  • Novartis AG and Sanofi.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Acute Myeloid Leukemia Market:

  • January 2022- Oncolyze reported that OM-301, which treats acute myeloid Leukemia (AML), had received FDA Orphan Drug Designation.

Acute myeloid leukemias (AMLs) are rare, extremely malignant neoplasms that cause a sizable fraction of cancer-related deaths. Curative therapies such as intensive chemotherapy and allogeneic stem cell transplantation only benefit a tiny number of younger and healthier patients. Still, the majority of older people have a dismal prognosis and survival rate. The prevalence of individuals with acute myeloid leukemia is growing along with the elderly population. The number of people affected with acute myeloid leukemia is also growing due to hazardous lifestyle choices, including drinking excessive amounts of alcohol and using tobacco. AML is also responsible for around 11,310 fatalities in U.S. Acute myeloid leukemia market growth is anticipated to propel throughout the forecast period due to rising illness prevalence. Furthermore, the rise of the global market is fuelled by the increased progress in pharmacology and molecular biology, which is assisting in discovering novel pharmaceuticals. Traditional therapies for this disorder have a history of causing tissue damage, nausea, and appetite loss and are ineffective at preventing relapses. These issues are causing entities to concentrate on various innovative and traditional tactics, such as stem cell treatment, serine-threonine protein kinases, and pipeline drugs. Acute myeloid leukemia treatment is becoming more popular as a result of government and non-governmental organizations promoting early cancer detection and treatment. Similar to how targeted treatments and biologics are being developed, the global market for acute myeloid leukemia is growing significantly. However, the market expansion is projected to be constrained by the high cost of available therapeutic therapy options. Chemotherapy, targeted therapy, and immunotherapy are costly treatment modalities that have been seen to hinder market expansion.

By Drug Class

  • Tyrosine Kinase Inhibitors
  • Hedgehog Pathway Inhibitors
  • Topoisomerase 2 Inhibitors
  • Others

By End User

  • Hospital
  • Clinic
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa  

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. The increased incidence of acute myeloid leukemia cases in the U.S. is anticipated to fuel market expansion in that region. For example, the American Society of Clinical Oncology reported in 2021 that acute myeloid leukemia is a rare cancer that makes up about 1% of all cancers. 20,240 individuals of all ages were expected to be affected by this disease in the U.S. in 2021 (11,230 men and boys and 9,010 women and girls). Adults account for most cases of AML, the second most common kind of leukemia in both adults and children. As a result, the rising incidence of acute myeloid leukemia in the U.S. will encourage more people to use this disease's therapies, which is anticipated to fuel the market's expansion in North America.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Acute Myeloid Leukaemia Market By Drug class, By End-user and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Acute Myeloid Leukemia Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.  Acute Myeloid Leukemia Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Myeloid Leukemia Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Acute Myeloid Leukemia Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Acute Myeloid Leukemia Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tyrosine Kinase Inhibitors
        2. Hedgehog Pathway Inhibitors
        3. Topoisomerase 2 Inhibitors
        4. Others

  • 8.  Acute Myeloid Leukemia Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital
        2. Clinic
        3. Others

  • 9.   North America Acute Myeloid Leukemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Acute Myeloid Leukemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Acute Myeloid Leukemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Acute Myeloid Leukemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Acute Myeloid Leukemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    •   1. Johnson And Johnson Private Limited
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pfizer Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Abbott
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AstraZeneca
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5 . Bayer
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6 . Celgene Corporation
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Ambit Biosciences Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Cyclacel Pharmaceuticals Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Novartis AG and Sanofi
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients